Penicillin allergy labels (PAL) are common but rarely correspond with a patient's likelihood to tolerate penicillin. This results in unnecessary penicillin avoidance in many patients, driving numerous negative health outcomes. Evaluation strategies for PAL are driven by risk stratification and include a spectrum of modalities such as delabeling without any testing, direct oral challenge, and skin testing followed by challenge testing. Historically, PAL delabeling has primarily been the domain of the allergist, but this has resulted in significant limitations in access to testing for many patients globally and in the United States. Novel strategies to increase access to penicillin allergy evaluations are urgently needed, and non-allergist delabeling has been proposed as one strategy to help address this. Using a pro/con format, we review the evidence for non-allergist PAL delabeling in children and adults, focusing on direct challenge testing and highlighting considerations to guide non-allergist implementation of penicillin allergy evaluations.
Keywords: delabeling; drug challenge; infectious disease; penicillin allergy; primary care; testing.
Copyright © 2024. Published by Elsevier Inc.